On April 19, 2024, Biogen released an update to the SMA community sharing recent data presentations from Spring conferences and latest updates from their SPINRAZA® (nusinersen) clinical development program. Read the full community statement here. “We aspire to address the unmet needs of the SMA community and are grateful to individuals throughout the community for […]
Biogen Releases SMA Community Letter Read More »
For the past seven years, the Cure SMA Community Update Survey has collected data and information on the SMA community’s experiences and daily challenges. Every single individual with SMA and their families bring a unique perspective that, collectively, help us adapt to the changing landscape of SMA. Data from the survey also informs Cure SMA’s
Participate in the Annual Cure SMA Community Update Survey – Open Now! Read More »
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board then ranks the submitted proposals on both their scientific merit and relevance to Cure SMA’s research priorities. Funding is awarded to the highest ranked projects.
Cure SMA’s year-long advocacy campaign to educate Congress and the Administration about the unmet needs of individuals with spinal muscular atrophy (SMA) has concluded with a major legislative victory. This weekend, the President signed into law a government funding bill that included a provision in support of new SMA research at the National Institutes of
Government Funding Bill Supports New SMA Research to Address Unmet Needs Read More »
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board then ranks the submitted proposals on both their scientific merit and relevance to Cure SMA’s research priorities. Funding is awarded to the highest ranked projects.
The study included 58 individuals with SMA types 2 and 3 who were treated with IV apitegromab for 52 weeks. At 36 months, treatment resulted in statistically significant improvements in motor function and mobility. Earlier this month, Scholar Rock shared that treatment with apitegromab was linked to improved muscle strength and range of motion, while
Apitegromab Linked to Improved Outcomes for Those with Spinal Muscular Atrophy Read More »
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board then ranks the submitted proposals on both their scientific merit and relevance to Cure SMA’s research priorities. Funding is awarded to the highest ranked projects.
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most participants treated with SPINRAZA after gene therapy Today Biogen, Inc. announced interim 6-month biomarker data
The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies1-6 Nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene
Today is Rare Disease Day and the rarest day of all, as this year’s occurrence takes place on February 29! In the U.S., spinal muscular atrophy (SMA) affects nearly 9,000 people. Yet, the SMA community is part of a greater community, the rare disease community, that comprises of 300 million people worldwide. Together, we create
Celebrate Rare Disease Day with Cure SMA Read More »
